Nova Scotia becomes sixth jurisdiction to implement biosimilar switching
As the Generics Bulletin reports, half of Canada’s provinces have now announced biosimilar switching policies.
Menu
Menu
Who we are
Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
About Biosimilars
As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.
Resources
Learn more about biosimilars and their benefits for patients and healthcare systems.
Latest news
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
Report from the AJMC Center for Biosimilars on Nova Scotia’s new biosimilar switching initiative.
Switch to biosimilar drugs may save N.S. millions of dollars
CBC News coverage of the announcement of Nova Scotia’s biosimilar switching policy, which is expected to save the province more than $13 million annually.